Sovereign patent lapses dismantle the global weight-loss monopoly ahead of schedule.
While brand-name drugmakers tightly defend their core Western patents, localized expirations in foreign jurisdictions fuel a rapid, low-cost wave of generic copycats that erodes pricing integrity.
The same conclusion keeps arriving from across the workspace's research — 2 topics independently instantiate this theme. Filter the evidence by where it came from:
Local patent expirations in South Africa have already opened the floodgates to generic competitors and forced defensive pricing strategies ahead of Western patent cliffs.
Hims capitalized on a localized patent lapse to launch a low-cost generic competitor in Canada ahead of Western timelines.
The expiration of brand patents in secondary national jurisdictions unleashes an immediate wave of regional generic copycats that erodes pricing power.